Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 601

Sort by

Sort Order Select

Journal Articles

Loss of BCL7A Permits IRF4 Transcriptional Activity and Cellular Growth in Multiple Myeloma

Chandraditya Chakraborty, Srikanth Talluri, Moritz Binder, Eugenio Morelli, Jessica Encinas Mayoral, Sanika Derebail, Anil Aktas Samur, Charles B. Epstein, Kenneth C. Anderson, Masood A Shammas, Mehmet K. Samur, Mariateresa Fulciniti, Nikhil C. Munshi

Blood blood.2024026588.

https://doi.org/10.1182/blood.2024026588

Published: 2025

Includes: Supplemental data

Journal Articles

Development of hyperdiploidy starts at an early age and takes a decade to complete

Mehmet K. Samur, Anil Aktas Samur, Parth Shah, Joseph S. Park, Mariateresa Fulciniti, Masood Shammas, Jill Corre, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2025) 145 (5): 520–525.

https://doi.org/10.1182/blood.2024025250

Published: 2025

Includes: Supplemental data

Journal Articles

Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset

Ariela Noy, Robert Ohgami, Nikhil C. Munshi, Imran Siddiqi, Kelley C. Dacus, Alicia Watson Saltis, Francis Shupo, Nicole Princic, Kristin Evans, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 797.

https://doi.org/10.1182/blood-2024-201745

Published: 2024

Journal Articles

Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 590.

https://doi.org/10.1182/blood-2024-204144

Published: 2024

Journal Articles

Synergistic Induction of Senescence-Driven Immune Responses and Myeloma Cell Cytotoxicity By CDK4/6 Inhibitors and Daratumumab Combination Therapy

Shiyi Xie, Zhen Yu, Mu Hao, Lu-Gui Qiu, Mariateresa Fulciniti, Nikhil C. Munshi, Yan Xu

Blood (2024) 144 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2024-200479

Published: 2024

Journal Articles

Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Blood (2024) 144 (Supplement 1): 149.

https://doi.org/10.1182/blood-2024-199890

Published: 2024

Journal Articles

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Nayda Bidikian, Francesco Corrado, Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Rosa Toenges, Jean-Baptiste Alberge, Michelle P. Aranha, Ting Wu, Michael Timonian, Shonali Midha, Elizabeth K. O'Donnell, Yuxin Liu, Sophie Magidson, Ashlee Strutevant, Kenneth C. Anderson, Nikhil C. Munshi, Omar Nadeem, Gad Getz, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 488.

https://doi.org/10.1182/blood-2024-207299

Published: 2024

Journal Articles

Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Bruno Paiva, Irene Manrique, Ethan G. Thompson, Timothy B. Campbell, Camila Guerrero, Nathan Martin, Larry D Anderson, Jr., Jesus G Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, Philippe Moreau, Jesús F. San-Miguel, Nikhil C. Munshi, Shari Kaiser

Blood (2024) 144 (Supplement 1): 900.

https://doi.org/10.1182/blood-2024-203007

Published: 2024

Journal Articles

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Blood (2024) 144 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2024-211352

Published: 2024

Journal Articles

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

Blood (2024) 144 (Supplement 1): 2972.

https://doi.org/10.1182/blood-2024-211759

Published: 2024

Journal Articles

Analysis of Alternative Splicing in Waldenstrom's Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates

Zachary R Hunter, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Abigail Peachey, Andres Felipe Ramirez Gamero, John M Hatcher, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C. Munshi, Shayna R Sarosiek, Jorge J. Castillo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 2986.

https://doi.org/10.1182/blood-2024-212123

Published: 2024

Journal Articles

Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies

Joanna Blocka, Seong Gu Heo, Shonali Midha, Nathaniel G. Tadros, Steffen B. Kulp, Julia Frede, Marius Mathies, Nikhil C. Munshi, Andrew J. Yee, Jens G. Lohr

Blood (2024) 144 (Supplement 1): 1898.

https://doi.org/10.1182/blood-2024-198713

Published: 2024

Journal Articles

Moderate-Severe Thrombocytopenia Portends Poor Outcomes in Multiple Myeloma

Grace M. Ferri, Cenk Yildirim, Joseph Park, Nhan V. Do, Mary T. Brophy, Nikhil C. Munshi, Camille V. Edwards, Nathanael R. Fillmore

Blood (2024) 144 (Supplement 1): 6930.

https://doi.org/10.1182/blood-2024-206352

Published: 2024

Journal Articles

The Mitochondrial Protease Clpp Is a Metabolic Vulnerability and an Immunogenic Trigger Against Multiple Myeloma

Tommaso Perini, Paola Zordan, Rossella Del Pizzo, Massimo Resnati, Ugo Orfanelli, Davide Stefanoni, Laura Cassina, Laura Oliva, Mehmet K. Samur, Lisa Viviani, Maria Materozzi, Matteo Trudu, Alessandra Boletta, Enrico Milan, Fabio Ciceri, Nikhil C. Munshi, Matteo Bellone, Simone Cenci

Blood (2024) 144 (Supplement 1): 765.

https://doi.org/10.1182/blood-2024-201364

Published: 2024

Journal Articles

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Anais Schavgoulidze, Mariateresa Fulciniti, Giulia Giorgetti, Sabrina Maheo, Shuhui Deng, Vanessa Favasuli, Srikanth Talluri, Masood A. Shammas, Luka Pavageau, Anil Aktas-Samur, Mehmet K. Samur, Herve Avet-Loiseau, Jill Corre, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 764.

https://doi.org/10.1182/blood-2024-199692

Published: 2024

Journal Articles

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Rosa Toenges, Jean-Baptiste Alberge, Francesco Corrado, Nayda Bidikian, David M. Cordas Dos Santos, Ankit K. Dutta, Elizabeth D. Lightbody, Romanos Sklavenitis Pistofidis, Adam S. Sperling, Kenneth C. Anderson, Shonali Midha, Yuxin Liu, Jacob P. Laubach, Eric L. Smith, Nikhil C. Munshi, Omar Nadeem, Irene Ghobrial, Gad Getz

Blood (2024) 144 (Supplement 1): 492.

https://doi.org/10.1182/blood-2024-204132

Published: 2024

Journal Articles

Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Maya D. Srinivasan, John Culnan, Mehar Hora, Alexander Lazzaro, Britney Bell, Geethika Bodanapu, Cenk Yildirim, June Corrigan, Nhan V. Do, Mary T. Brophy, Nikhil C. Munshi, Raphael E. Szalat, Nathanael R. Fillmore, Camille V. Edwards

Blood (2024) 144 (Supplement 1): 5169.

https://doi.org/10.1182/blood-2024-211465

Published: 2024

Journal Articles

A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies

Elena Maroto Martin, Yingjie Zhao, Sara Mangesh Kolhatkar, Roberto Garcia-Vicente, Mubin Tarannum, Mehmet K. Samur, Mariateresa Fulciniti, Rizwan Romee, Jianzhu Chen, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2024-208607

Published: 2024

Journal Articles

Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

Elizabeth K. O'Donnell, Clifton C. Mo, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil C. Munshi, Shonali Midha, Diana Cirstea, Paul G. Richardson, Noopur Raje, Andrew J. Yee

Blood (2024) 144 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2024-201768

Published: 2024

Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3360.

https://doi.org/10.1182/blood-2024-202653

Published: 2024

NARROW

Loss of BCL7A Permits IRF4 Transcriptional Activity and Cellular Growth in Multiple Myeloma

Development of hyperdiploidy starts at an early age and takes a decade to complete

Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset

Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Synergistic Induction of Senescence-Driven Immune Responses and Myeloma Cell Cytotoxicity By CDK4/6 Inhibitors and Daratumumab Combination Therapy

Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

Analysis of Alternative Splicing in Waldenstrom's Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates

Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies

Moderate-Severe Thrombocytopenia Portends Poor Outcomes in Multiple Myeloma

The Mitochondrial Protease Clpp Is a Metabolic Vulnerability and an Immunogenic Trigger Against Multiple Myeloma

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies

Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only